BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name “TNF Pharmaceuticals, Inc.,” effective today.

巴尔的摩--（商业新闻短讯）--TNF Pharmaceuticals，Inc.，前身为MyMD Pharmaceuticals，Inc.（纳斯达克：MyMD）（“公司”），一家临床阶段的生物制药公司，致力于开发针对与年龄有关的疾病以及自身免疫和炎症状况的新型疗法，今天宣布将更名为“TNF Pharmaceuticals，Inc.”，从今天起生效。

The Company’s common stock, listed on the Nasdaq Capital Market, will begin trading under the new stock symbol “TNFA,” effective before the market open on Wednesday, July 24, 2024..

该公司在纳斯达克资本市场上市的普通股将在2024年7月24日（星期三）开市前以新股票代号“TNFA”开始交易。。

“Our new name, TNF Pharmaceuticals, is more closely aligned with our scientific focus on TNF-alpha, a protein in the body that plays a key role in inflammation and autoimmunity,” said the Company’s President and Chief Medical Officer Mitchell Glass, M.D. “Excess TNF-α in the blood or tissue can lead to diseases and disorders marked by acute or chronic inflammation, including age-related disorders.

该公司总裁兼首席医疗官Mitchell Glass医学博士说：“我们的新名字TNF Pharmaceuticals与我们对TNF-α的科学关注更加吻合，TNF-α是人体内一种在炎症和自身免疫中起关键作用的蛋白质。血液或组织中过多的TNF-α会导致以急性或慢性炎症为特征的疾病，包括与年龄有关的疾病。

Our lead clinical candidate, MYMD-1®, blocks the activity of excess TNF-alpha which supports restoration of control and regulation of the immune system.”.

我们的主要临床候选药物MYMD-1®可阻断过量TNF-α的活性，从而支持恢复对免疫系统的控制和调节。”。

MYMD-1 is a novel, orally dosed TNF-alpha (TNF-α) inhibitor drug for treating multiple conditions related to immune-metabolic dysregulation. A successful and statistically significant small Phase 2 study was completed in 2023, evaluating the safety and efficacy of MYMD-1 as a treatment for sarcopenia, the progressive loss of muscle mass and strength associated with aging..

MYMD-1是一种新型口服TNF-α（TNF-α）抑制剂药物，用于治疗与免疫代谢失调有关的多种疾病。2023年完成了一项成功且具有统计学意义的小型2期研究，评估了MYMD-1治疗肌肉减少症（与衰老相关的肌肉质量和力量的逐渐丧失）的安全性和有效性。。

“We are moving forward with mid-stage clinical trials of MYMD-1 in sarcopenia based on positive clinical data from our Phase 2 trial and previous research findings,” Dr. Glass continued. “We believe MYMD-1 could become a transformative treatment for TNF-alpha-based autoimmune and inflammatory diseases including age-related conditions.”.

格拉斯博士继续说：“我们正在根据第二阶段试验的阳性临床数据和之前的研究结果，推进MYMD-1在肌肉减少症中的中期临床试验。”。“我们相信MYMD-1可能成为基于TNF-α的自身免疫性和炎症性疾病（包括与年龄相关的疾病）的变革性治疗方法。”。

MYMD-1 is distinguished from currently marketed TNF-α blockers in multiple ways. It is a first-in-class oral treatment shown to reduce TNF-α and inflammation without infusion or injection. The drug’s ease of oral dosing is a strong advantage over currently available TNF-α blockers, none of which are dosed orally.

MYMD-1以多种方式与目前市售的TNF-α阻滞剂区别开来。这是一种一流的口服治疗方法，可以减少TNF-α和炎症，无需输注或注射。与目前可用的TNF-α阻滞剂相比，该药物易于口服给药是一个强大的优势，而TNF-α阻滞剂均未口服给药。

Unlike systemic therapies, our oral TNF alpha inhibitor can be dose adjusted acutely and chronically for maximal safety and efficacy depending on the patient’s need..

与全身治疗不同，我们的口服TNF-α抑制剂可以根据患者的需要进行急性和慢性剂量调整，以获得最大的安全性和有效性。。

TNF Pharmaceuticals retains the registered trademark MYMD-1® for its lead drug program. The Company’s new Investors website address is ir.tnfpharma.com.

。该公司的新投资者网站地址是ir.tnfpharma.com。

About TNF Pharmaceuticals, Inc.

关于TNF制药公司。

TNF Pharmaceuticals, Inc., formerly known as MyMD Pharmaceuticals, Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1® is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.

TNF Pharmaceuticals，Inc.，原名MyMD Pharmaceuticals，Inc.，一家致力于延长健康寿命的临床阶段制药公司，专注于开发两种新型治疗平台，以治疗疾病的原因，而不仅仅是解决症状。MYMD-1®是一种基于临床阶段小分子的药物平台，可调节免疫系统以控制驱动慢性炎症的TNF-α和其他促炎细胞信号细胞因子。

MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs..

MYMD-1正在开发用于治疗以急性或慢性炎症为特征的疾病和病症。该公司的第二个药物平台Supera CBD正在开发中，用于治疗慢性疼痛、成瘾和癫痫。Supera CBD是大麻二酚（CBD）的一种新型合成衍生物，正在开发中，以应对和改善快速增长的CBD市场，其中包括FDA批准的药物和目前未作为药物监管的CBD产品。。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements.

本新闻稿可能包含前瞻性声明。这些前瞻性陈述涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致实际结果、绩效或成就与任何预期的未来结果、绩效或成就存在重大差异。

Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements.

前瞻性声明仅在发布之日起生效，公司及其附属公司均不承担更新前瞻性声明的任何义务。诸如“预期”、“相信”、“可能”、“估计”、“预期”、“可能”、“计划”、“将”、“将”等词语以及其他类似的表达方式旨在识别这些前瞻性陈述。

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company’s ability to maintain compliance with the Nasdaq Stock Market’s listing standards; the timing of, and the Company’s ability to, obtain and maintain regulatory approvals for clinical trials of the Company’s pharmaceutical candidates; the timing and results of the Company’s planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company’s ability to retain and attract senior management and other key employees; the Company’s ability to quickly and effectively respond to new technological developments; and the Company’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company’s proprietary rights.

可能导致实际结果与此类前瞻性声明所示结果产生重大差异的重要因素包括但不限于：公司保持符合纳斯达克股票市场上市标准的能力；公司获得和维持公司候选药物临床试验监管批准的时间和能力；该公司计划对其候选药物进行临床试验的时间和结果；公司为其候选药物所需的资金数额；竞争程度提高；一般政治、经济或监管条件以及公司运营所在市场的变化；公司留住和吸引高级管理人员和其他关键员工的能力；公司快速有效应对新技术发展的能力；以及公司保护其商业秘密或其他专有权利，在不侵犯他人专有权利的情况下运营以及防止他人侵犯公司专有权利的能力。

A discussion.

讨论。